Zum Hauptinhalt springen
Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Alpha-glucosidase Inhibitors -  Usman Ghani

Alpha-glucosidase Inhibitors (eBook)

Clinically Promising Candidates for Anti-diabetic Drug Discovery

(Autor)

eBook Download: EPUB
2019 | 1. Auflage
242 Seiten
Elsevier Science (Verlag)
978-0-08-102628-1 (ISBN)
Systemvoraussetzungen
213,93 inkl. MwSt
(CHF 208,95)
Der eBook-Verkauf erfolgt durch die Lehmanns Media GmbH (Berlin) zum Preis in Euro inkl. MwSt.
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
Alpha-glucosidase Inhibitors: Clinically Promising Candidates for Anti-diabetic Drug Discovery presents information that researchers can use to address a whole host of promising leads for the development of novel, oral, anti-diabetic drugs with improved efficacy and fewer side effects. Beginning with a discussion of the huge potential of a -glucosidase inhibitor leads and adaptations, and highlighting their importance within the field of anti-diabetic drug discovery, the book provides chemical structures, detailed background information and in vivo and in vitro biological activity data, and more economical adaptations of these structures. Drawing on the author's expert research in the field, this book highlights promising leads for development and helps researchers select the most appropriate inhibitors for their own work. It is a useful tool not only for anti-diabetic drug development researchers, but also for those whose research may be enhanced by an understanding of a -glucosidase inhibitor chemistry and activity. - Identifies and presents promising a-glucosidase inhibitors of natural and synthetic origin that belong to a variety of chemical classes - Compiles chemical structures and detailed in vivo and in vitro biological activity data that will help researchers select inhibitors for further work - Discusses promising avenues and potential challenges in the development of new a-glucosidase inhibitors based on their activity data

Usman Ghani is Assistant Professor of Biochemistry at King Saud University (KSU), Saudi Arabia. After gaining experience as a Chemist and Researcher in Pakistan, he completed his PhD at the University of Alberta, Canada, and took up a Postdoctoral Fellowship there before moving to KSU in 2005. He has been awarded numerous research grants and has published 23 papers to date.Prof Ghani's current research involves screening and identification of clinically important enzyme inhibitors and studies on their mechanism of inhibition. His team has identified a number of synthetic and natural inhibitors of tyrosinase and alpha-glucosidase enzymes that may become potential candidates for development into drugs for the treatment of hyperpigmentation and diabetes respectively.
Alpha-glucosidase Inhibitors: Clinically Promising Candidates for Anti-diabetic Drug Discovery presents information that researchers can use to address a whole host of promising leads for the development of novel, oral, anti-diabetic drugs with improved efficacy and fewer side effects. Beginning with a discussion of the huge potential of a -glucosidase inhibitor leads and adaptations, and highlighting their importance within the field of anti-diabetic drug discovery, the book provides chemical structures, detailed background information and in vivo and in vitro biological activity data, and more economical adaptations of these structures. Drawing on the author's expert research in the field, this book highlights promising leads for development and helps researchers select the most appropriate inhibitors for their own work. It is a useful tool not only for anti-diabetic drug development researchers, but also for those whose research may be enhanced by an understanding of a -glucosidase inhibitor chemistry and activity. - Identifies and presents promising a-glucosidase inhibitors of natural and synthetic origin that belong to a variety of chemical classes- Compiles chemical structures and detailed in vivo and in vitro biological activity data that will help researchers select inhibitors for further work- Discusses promising avenues and potential challenges in the development of new a-glucosidase inhibitors based on their activity data
Erscheint lt. Verlag 19.11.2019
Sprache englisch
Themenwelt Medizin / Pharmazie Gesundheitsfachberufe
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Naturwissenschaften Chemie Organische Chemie
ISBN-10 0-08-102628-5 / 0081026285
ISBN-13 978-0-08-102628-1 / 9780081026281
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
EPUBEPUB (Adobe DRM)

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich